Oral and Poster Presentation 45th Annual ARA NSW-ACT Branch Meeting 2023

Rheumatic immune-related adverse effects of checkpoint inhibitors (#24)

Arupam AR Raman 1 2 , Kim KB Biddington 2 , Fathima Insaaf IZA Zahir Ahamed 2 , Kathleen KT Tymms 2 , Chandima CP Perera 2 , Katie KM Morrisroe 2
  1. Prince of Wales Hospital, Sydney, NSW, Australia
  2. Canberra Health Services, Canberra, ACT, Australia

 

Background: Checkpoint inhibitor immunotherapies (CPI) have revolutionized the treatment of malignancies. Aberrant T-cell activation secondary to CPI may lead to immune toxicities, named immune-related adverse effects (irAEs).

Objective: Determine the predictors of rheumatic irAEs and the frequency of concurrent irAEs, compare the presence of autoantibodies, raised inflammatory markers and imaging with traditional rheumatic diseases and describe the management approach of rheumatic irAEs and their prognosis.

Methods: Retrospective cohort study at Canberra Health Services of adults with malignancies treated with CPI from July 2011 to September 2022.

Results: We have identified 41 from 875 patients to date who developed rheumatic irAEs, and 15 patients were referred to Rheumatology at Canberra Health Services. Data will be presented at the 45th ARA NSW ACT Branch Meeting.

 

  1. Kim H, Comey S, Hausler K, Cook G. A real world example of coverage with evidence development in Australia - ipilimumab for the treatment of metastatic melanoma. J Pharm Policy Pract. 2018;11:4.
  2. Chatzidionysiou K, Liapi M, Tsakonas G, Gunnarsson I, Catrina A. Treatment of rheumatic immune-related adverse events due to cancer immunotherapy with immune checkpoint inhibitors-is it time for a paradigm shift? Clin Rheum atol. 2021;40(5):1687-95.
  3. Cretu I, Cretu B, Cirstoiu C, Cursaru A, Milicescu M, Bojinca M, et al. Rheumatological Adverse Events Following Immunotherapy for Cancer. Medicina (Kaunas). 2022;58(1):94.
  4. Shen P, Deng X, Hu Z, Chen Z, Huang Y, Wang K, et al. Rheumatic Manifestations and Diseases From Immune Checkpoint Inhibitors in Cancer Immunotherapy. Front Med (Lausanne). 2021;8:762247.
  5. Kostine M, Finckh A, Bingham CO, Visser K, Leipe J, Schulze-Koops H, et al. EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. Ann Rheum Dis. 2021;80(1):36-48.
  6. Zhang S, Zhou Z, Wang L, Li M, Zhang F, Zeng X. Rheumatic immune-related adverse events associated with immune checkpoint inhibitors compared with placebo in oncologic patients: a systemic review and meta-analysis. Therapeutic Advances in Chronic Disease. 2021;12:2040622320976996.
  7. Alexander S, Swami U, Kaur A, Gao Y, Fatima M, Ginn MM, et al. Safety of immune checkpoint inhibitors in patients with cancer and pre-existing autoimmune disease. Ann Transl Med. 2021;9(12):1033.
  8. Steven NM, Fisher BA. Management of rheumatic complications of immune checkpoint inhibitor therapy - an oncological perspective. Rheumatology (Oxford). 2019;58(Suppl 7):29-39.